Oncolytics Biotech (TSE:ONC) Share Price Passes Above Two Hundred Day Moving Average of $2.58

Oncolytics Biotech Inc. (TSE:ONCGet Free Report)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$2.58 and traded as high as C$3.04. Oncolytics Biotech shares last traded at C$2.96, with a volume of 98,113 shares.

Analyst Upgrades and Downgrades

Separately, Jonestrading set a C$9.00 target price on shares of Oncolytics Biotech and gave the company a “buy” rating in a report on Wednesday, May 24th.

Check Out Our Latest Stock Analysis on Oncolytics Biotech

Oncolytics Biotech Trading Down 2.7 %

The firm’s fifty day simple moving average is C$3.27 and its 200 day simple moving average is C$2.58. The stock has a market capitalization of C$211.31 million, a P/E ratio of -6.70 and a beta of 1.74. The company has a debt-to-equity ratio of 2.15, a quick ratio of 8.86 and a current ratio of 11.69.

Oncolytics Biotech (TSE:ONCGet Free Report) last announced its quarterly earnings results on Monday, August 14th. The company reported C($0.12) earnings per share for the quarter, meeting the consensus estimate of C($0.12). As a group, equities research analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

(Get Free Report)

Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

Featured Articles

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.